Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab + pertuzumab with taxane chemotherapy versus endocrine therapy in operable HER2-positive/hormone receptor-positive breast cancer
2016-005157-21Phase 2Completed
- Sponsor
- Palleos Healthcare
- Start
- Mar 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab, trastuzumab, paclitaxel, tamoxifen, anastrozole and 6 more in breast cancer (2 arms), sponsored by Palleos Healthcare. Primary endpoint: Pathologic complete response. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-005157-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005157-21.